Audit: QRS - Thymosin Beta-4 for Health & Longevity

Audit conducted on 06/09/2026 03:46 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	84
Failed	0
N/A	9
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Spot-checked every populated span against the ER: protocol cells vs ER lines 314/318/320, time cells vs line 368, benefit and risk items vs the ER tier headings, contraindications vs lines 286-292, interactions vs lines 264-282, markers vs the ER table lines 400-406. All literally supported.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	Hedges carried through: “route and dose untested” (action_3_sub), “No target; no validated clinical assay” (marker_7_target), “unknown effects of long-term dosing” (risks_speculative), “long-term self-injection is untested” (at_a_glance).
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	No strengthening or softening found. The two ⚠️ Conflicted Low benefits are neither upgraded nor dropped, and the at_a_glance keeps the ER’s “the largest trials did not confirm it”.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications come only from the ER’s “Populations who should avoid” list; caution_items only from the ER interaction bullets. No Benefit- or Risk-Modifying Factor is surfaced as a gate.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	Brand and product names used (ReGenTree, HLB Therapeutics, RegeneRx, RGN-259, BPC-157) all appear in the ER for the same facts. No PMIDs, NCT IDs, author names or sample sizes carried over.
1.6	The QRS does not introduce new attributions.	🟢	No attribution appears that is not in the ER; sponsor names in action_1_label and action_2_label are the ER’s own bold labels.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Matches the ER’s sober, qualified register — no High benefit tier, explicit untested-route flags.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Expert, objective and data-driven; tiering plus concrete targets and doses let the reader act on the evidence rather than be told what to do.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Presents thresholds and tiers as evidence, not orders; no imperative addressed to a patient.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No prescriptive or clinical-advice phrasing; the fixed footer disclaimer is intact.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	Content is stated as findings and protocols observed in trials or clinics, not as recommendations.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person address anywhere in the document (verified: no “you”/”your”).
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Plain language throughout; residual terms (neurotrophic keratopathy, Child-Pugh, NYHA class) are load-bearing decision qualifiers carried verbatim from the ER.
2.8	Information is presented in a concise and very compact manner	🟢	Every item is stripped to its key fact; no trailing rationale in any gate, benefit or risk item.
2.9	It DOES NOT address the reader directly	🟢	Confirmed — the reader is never addressed.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Surfaces the subcutaneous clinic protocol and self-sourcing risk, which is what this audience actually faces.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Assumes willingness to run a 7-marker baseline panel, cancer screening and a supervised dosing course.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Not pitched at the general population — it assumes an unapproved peptide is being actively considered.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	Risk/benefit weighting is audience-specific: the ER’s IV cardiac protocol is set aside in favour of the routes this audience can act on, with route and dose flagged untested.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“peptide and longevity clinics” (action_3_label); no occurrence of “anti-aging” anywhere.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Formal register throughout — “adverse events”, “subcutaneous”, “hypersensitivity”, “injection-site reactions”; no consumer-grade substitutes.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	Diff against the template confirms every fixed heading, gate heading, tier label and Monitoring column header is byte-identical.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 34 template variable names present; 61 spans total (marker_#* expanded to 7 rows, qualitative_item# to 6 items).
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Diff against the template shows changes only inside data-qrs-var spans and the frontmatter; the website=”evidence_review”/”audit”/”full_review” spans, CSS and footer are untouched.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No ER section feeding the QRS is empty. The ER’s High-benefit subsection carries explanatory prose rather than empty-state phrasing, and item 12.5 governs that case.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	ER bold labels reused verbatim: “Ophthalmic protocol (ReGenTree and HLB Therapeutics)”, “Topical dermal protocol (RegeneRx)”, “Subcutaneous protocol used in peptide and longevity clinics”.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Benefit, risk and marker labels reproduce the ER headings and table rows without paraphrase or invention.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji present in the file; tiers conveyed by bold labels and CSS colour only.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed to the limit the other checklist items permit — all trailing clauses stripped, glosses dropped, marker rationales reduced to one clause — with no content spilled into an appended block.

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	The metadata comment opens on line 2, immediately after <!doctype html>, before any other content.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	YAML opens at line 3 and closes at line 13; the preceding descriptive line sits outside the delimiters.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Wrapped in an HTML comment; no rendered element repeats the values.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	All values trimmed and unquoted except duration: “00:03”, which contains a colon and requires quoting.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	er_filename: thymosin_beta_4_2026-0906-0011_Opus_ER.md — matches the source ER on disk.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	qrs_prompt_version: 26.7.02 — matches the version badge at the top of QRS.md.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	qrs_creation_date: 2026-0906-0254 — correct YYYY-MMDD-HHMM form.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	qrs_creator_ai_nickname: Opus
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	Single word, no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	qrs_creator_ai_fullname: Opus 5
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	Nickname plus version number, no additional qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	qrs_filename: thymosin_beta_4_2026-0906-0011_Opus_QRS.html — matches the actual filename.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified: no stray whitespace or unnecessary quoting on any key.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	— canonical_topic plus the required suffix, ampersand entity-encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	header_topic is the canonical_topic with & encoded.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	09/06/2026 — correct MM/DD/YYYY rendering of qrs_creation_date 2026-0906.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	header_subline_model: Opus 5, matching qrs_creator_ai_fullname.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header carries only the title and the template subline; no badge, AKA line, version stamp or variant marker.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Condenses the ER Conclusion (lines 435-437) into the decision-relevant core: what worked, what did not replicate, what rests on animals, and the safety gap.
7.2	[at_a_glance] is no longer than 60 words	🟢	58 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each clause traces to a distinct Conclusion passage — eye drops/largest trials, gel and scalp flaking, ulcers at one concentration, animal-only claims, supervised-dosing safety, tissue studies and cancer spread.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms or technical classifications; “body-made repair protein”, “eye drops”, “scalp flaking”, “cancer spread” are all everyday terms.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial names, years, sample sizes or p-values.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No effect sizes, risk ratios or statistical results.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	Drawn from the ER’s “Populations who should avoid Thymosin Beta-4” list, lines 286-292.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All seven ER contraindications represented, one-to-one.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Seven <li> elements inside the stop_items span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Trailing rationale stripped throughout — e.g. the WADA item drops “in which thymosin-β4 and its derivatives are prohibited at all times” and the renal/hepatic item drops “where no exposure data exist”.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Qualifiers preserved: “within 5 years”, “(except non-melanoma skin cancer)”, “Within 6 months”, “Class III–IV”, “eGFR below 30 mL/min/1.73 m²”, “Child-Pugh Class B or C”.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in its contraindication list.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	Section is populated, and the ER does identify populations that should avoid the intervention.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	Drawn from the ER’s interaction bullets, lines 264-282.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Nine of the ten ER bullets carried; the omitted one is the antihistamine/proton-pump-inhibitor bullet the ER itself marks “no interaction identified”, which is not an interaction. None duplicates a contraindication.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Nine <li> elements inside the caution_items span.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	All em-dash trailing clauses stripped — “— additive, monitor”, “— caution, opposing action”, “— additive, unstudied”, “— additive, benign” — leaving only the agent class.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Every ER example-drug list preserved in full, including the four-item supplement lists.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in its interaction list.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	Section is populated, and the ER does identify interactions.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	Derived from the ER Therapeutic Protocol section, lines 312-336.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	The three self-administrable routes with dosing detail — ophthalmic, topical dermal and subcutaneous — are the actionable set; the ER’s IV cardiac bullet is an in-hospital acute protocol with no implementation path for this audience.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER describes more than three distinct actionable implementation aspects.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine action cells populated with ER-derived content; no placeholder text remains.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Ocular symptoms, corneal defect closure and chronic ulcer closure — the only three time-to-effect figures the ER states (line 368).
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Order follows the ER’s own benefit ordering within the Low tier: dry eye relief, corneal defect healing, ulcer closure. The Medium-tier scalp benefit has no stated time-to-effect in the ER.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER states three distinct time-to-effect aspects.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine time cells populated with ER-derived content.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER does provide time-to-effect information, so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	Derived from the ER Expected Benefits section, lines 124-184.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four benefit spans present and correctly bound.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Items reduced to the ER tier headings alone; no magnitudes, p-values, sample sizes or mechanisms carried over.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parenthetical content survives; the ER’s ⚠️ Conflicted markers are also correctly dropped per item 4.4.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	benefits_high carries no items in the ER and is correctly set to style=”display: none” with an empty body, not an empty-state phrase.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	Derived from the ER Potential Risks & Side Effects section, lines 200-246.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four risk spans present and correctly bound.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Items reduced to the ER tier headings alone; no frequencies, mechanisms or study details carried over.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parenthetical content survives.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four risk tiers carry items in the ER, so no span needs suppressing.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Derived from the ER Monitoring Protocol & Defining Success section, lines 392-406.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All seven biomarker rows of the ER table reproduced with their functional targets and rationales.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Populated from ER line 396 — baseline, 6 weeks and course end, then every 6–12 months, with cancer screening on the normal age-appropriate schedule.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	Derived from the qualitative marker list at ER lines 410-415.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All six qualitative markers reproduced, in the ER’s order.

Issues 06/09/2026 03:46

Pass rate 100.00%. No issues found.

Issues 06/09/2026 03:43

1. 1.1 / 1.3 — Cancer risk evidence overstated: marker_6_why (line 712) reads “the only risk with human evidence”, while the ER says “the only risk with human tissue evidence” (ER lines 296 and 405); dropping “tissue” broadens the claim and contradicts the ER’s High-tier risk, which rests on human trial data.

Fixes 06/09/2026 03:43

1. 1.1 / 1.3 — Cancer risk evidence overstated: Restored the ER’s qualifier in marker_6_why, changing “the only risk with human evidence” to “the only risk with human tissue evidence”.

Issues 06/09/2026 03:38

1. 4.5 — Sheet exceeds one A4 page: At the template’s print geometry the populated sheet runs roughly 1.7 A4 pages; the Contraindications and Key Interactions gates, the seven-row Monitoring table and several Protocol cells all wrap to two or three lines where the per-section budget allows one.

Fixes 06/09/2026 03:38

1. 4.5 — Protocol sub cells condensed: Trimmed all three action_#_sub cells and time_3_sub to the per-cell budget, e.g. “Preservative-free RGN-259; 14–28 days in dry eye, 28 days in keratopathy” to “Preservative-free RGN-259; 14–28 days”.
2. 4.5 — Contraindications gate condensed: Shortened the seven stop_items to fewer wrapped lines while keeping every threshold, time window and severity class, e.g. “Active malignancy, or malignancy treated within 5 years (except treated non-melanoma skin cancer)” to “Active malignancy, or treated within 5 years (except non-melanoma skin cancer)”.
3. 4.5 — Monitoring cells condensed: Tightened five marker_#_why cells and the marker_3_target, marker_6_target and marker_7_target cells so each table row wraps less, e.g. “No established target; no validated clinical assay available” to “No target; no validated clinical assay”.
4. 4.5 — Monitoring cadence condensed: Reworded monitoring_cadence from “and every 6–12 months if courses are repeated” to “then every 6–12 months if repeated” to drop a wrapped line.

Issues 06/09/2026 03:27

1. 1.3 — Tumour risk evidence overstated: [marker_6_why] (line 733) says the tumour-signalling concern is “the only risk with human evidence”, while the ER says “human tissue evidence” (ER lines 296, 405); as written it also contradicts the ER’s High and Medium risks, which rest on human trial data.
2. 4.3 — Interaction label paraphrased: Line 598 uses “Supplements affecting vessels or platelets” instead of the ER’s bold label “Supplements with additive vessel-growth or antiplatelet effects” (ER line 278).
3. 8.5 — Severity class dropped: Line 577 reads “Kidney impairment (eGFR below 30 mL/min/1.73 m²)”; the ER contraindication is “severe kidney impairment” (ER line 292), and the severity class must be preserved.

Fixes 06/09/2026 03:27

1. 1.3 — Tumour risk evidence overstated: [marker_6_why] changed from “the only risk with human evidence” to “the only risk with human tissue evidence”, matching the ER wording.
2. 4.3 — Interaction label paraphrased: Replaced the paraphrased interaction label “Supplements affecting vessels or platelets” with the ER’s verbatim label “Supplements with additive vessel-growth or antiplatelet effects”.
3. 8.5 — Severity class dropped: Restored the ER’s severity class in the contraindication, changing “Kidney impairment (eGFR below 30 mL/min/1.73 m²)” to “Severe kidney impairment (eGFR below 30 mL/min/1.73 m²)”.

Issues 06/09/2026 03:22

1. 4.5 — Content exceeds one A4 page: At print width the header, at-a-glance, protocol panel, benefits card and decision gates already fill the A4 content height, pushing the Risks, Monitoring and Qualitative Assessment cards (QRS lines 619–805) onto a second page; the wordiest non-mandated spans — action subs, time subs, marker “Why” text, cadence and qualitative items — are not condensed to the per-section budget.

Fixes 06/09/2026 03:22

1. 4.5 — At-a-glance tightened: Replaced “though the largest trials did not confirm it” with “but the largest trials did not confirm it”, “appeared at one strength only” with “came at one strength only”, and “longer self-injection is untested; tissue studies link” with “long-term self-injection is untested, and tissue studies link”, saving a wrapped line.
2. 4.5 — Protocol sub-cells condensed: action_2_sub changed from “Applied to a cleaned, compression-dressed chronic ulcer; 0.03% gave the clearest signal” to “Cleaned, compression-dressed chronic ulcer; 0.03% gave the clearest signal”, and action_3_sub from “For 4–6 weeks, then every one to two weeks. No trial has evaluated this route, dose or schedule” to “4–6 weeks, then every 1–2 weeks; no trial has evaluated this route or dose”, dropping the protocol row from three sub-lines to two.
3. 4.5 — Time-to-effect sub condensed: time_3_sub changed from “In venous stasis and pressure ulcers; musculoskeletal timelines are anecdotal” to “Venous stasis and pressure ulcers; musculoskeletal timelines anecdotal”.
4. 4.5 — Contraindication items trimmed: Shortened four gate items (“Active malignancy, or malignancy treated within 5 years (except treated non-melanoma skin cancer)”; “Within 6 months of acute coronary syndrome, stroke or transient ischaemic attack; New York Heart Association Class III–IV heart failure”; “Hypersensitivity to peptide or biologic products”; “Kidney impairment (eGFR below 30 mL/min/1.73 m²) or liver impairment at Child-Pugh Class B or C”), cutting three wrapped lines while keeping every time window, threshold and severity class.
5. 4.5 — Key interaction item trimmed: Changed “Supplements with additive vessel-growth or antiplatelet effects (fish oil, curcumin, high-dose vitamin E, ginkgo)” to “Supplements affecting vessels or platelets (fish oil, curcumin, high-dose vitamin E, ginkgo)”, preserving the full example-drug list.
6. 4.5 — Monitoring cells condensed: Tightened six marker cells — marker_1_why to “Tracks the inflammation the peptide is proposed to reduce”, marker_2_why to “Platelets store this peptide; detects injection-related infection”, marker_4_why to “Kidney enzymes clear this peptide; severe impairment is an exclusion”, marker_5_why to “Poor blood-sugar control impairs the wound healing being targeted”, marker_6_why to “…the only risk with human evidence”, and marker_7_target/why to “No established target; no validated clinical assay available” / “Would detect the immune response seen in Phase 1”.
7. 4.5 — Monitoring cadence condensed: Rewrote the cadence line to “Baseline, then metabolic panel and inflammatory marker at 6 weeks and course end, and every 6–12 months if courses are repeated. Cancer screening on the normal age-appropriate schedule.”, saving a wrapped line without dropping any interval.

Issues 06/09/2026 03:15

1. 1.1 — NYHA clause pulled into 6-month window: Contraindication 3 (QRS line 571) drops the ER’s “with” before “New York Heart Association Class III–IV heart failure”, so the “Within 6 months of” window reads as governing the heart-failure clause, which the ER (line 288) does not do.

Fixes 06/09/2026 03:15

1. 1.1 — NYHA clause scope restored: Restored the ER’s “with” before “New York Heart Association Class III–IV heart failure” in contraindication 3, so the “Within 6 months of” window no longer reads as governing the heart-failure clause.

Issues 06/09/2026 03:09

1. 11.4 — Time-to-effect sub misattributed: [time_3_sub] at QRS lines 524–526 carries “Musculoskeletal timelines are anecdotal” under the “Chronic ulcer closure / Up to 3 months” cell, where the ER (line 368) states it as a separate caveat; the ulcer cell is left without its own context and the anecdotal caveat reads as if it qualified the three-month figure.

Fixes 06/09/2026 03:09

1. 11.4 — Time-to-effect sub misattributed: Replaced [time_3_sub] “Musculoskeletal timelines are anecdotal” with “In venous stasis and pressure ulcers; musculoskeletal timelines are anecdotal”, giving the chronic ulcer cell its own ER-derived context while keeping the ER’s separate anecdotal-timeline caveat.

Issues 06/09/2026 03:02

1. 4.5 — Sheet overruns one A4 page: Several cells carry ER prose uncondensed — marker_6target (line 737), marker_7_target (line 754) and monitoring_cadence (line 770) reproduce whole ER sentences, time_1_sub and time_2_sub (lines 504, 516) only restate their own label and value, and the three action#_sub cells each wrap to four lines in a one-third-width column — pushing the rendered sheet well past a single A4 page.

Fixes 06/09/2026 03:02

1. 4.5 — Monitoring target cells condensed: marker_6_target was cut from “No established target for this use; the individual’s own baseline is the reference, and change from it is what is tracked” to “No established target; the individual’s own baseline is the reference”, and marker_7_target from the full ER sentence to “No established target; no validated clinical assay is commercially available”.
2. 4.5 — Monitoring why cell shortened: marker_2_why was cut from “Platelets are the body’s main store of this peptide; also detects injection-related infection” to “Platelets store this peptide; also detects injection-related infection”.
3. 4.5 — Monitoring cadence tightened: monitoring_cadence was reduced from 237 to 212 characters by folding “repeated at 6 weeks, at the end of the first course” into “at 6 weeks and at course end”.
4. 4.5 — Time-to-effect subs no longer restate label: time_1_sub, time_2_sub and time_3_sub were replaced with the distinct trial context they lacked — “Measured in the dry eye trials”, “In neurotrophic keratopathy” and “Musculoskeletal timelines are anecdotal” — instead of repeating their own label and value.
5. 4.5 — Protocol sub cells shortened: action_1_sub dropped the dosing frequencies already shown in action_1_value, action_2_sub was tightened to “0.03% gave the clearest signal”, and action_3_sub dropped the repeated “2–2.5 mg”, bringing each three-column cell down by a wrapped line.